Aspen Neuroscience, a new San Diego biotech company working on stem cell treatment for Parkinsons disease, has come out of stealth mode and raised $6.5 million to pursue clinical testing for its therapy. Co-founded by well-known stem cell scientist Jeanne Loring, Aspen Neuroscience proposes creating stem cells from modified skin cells of Parkinsons patents via genetic engineering. Continue reading →

Why do we stop dancing when we grow up? Why do we disconnect and alienate ourselves from the body? Continue reading →

Experts discover bizarre link between electronic brain implant used to emit electrical impulses and the ability to swim. Imagine being an avid swimmer, having practiced and enjoyed the sport your entire life, only to have the skill stripped away Continue reading →

The progression of Parkinsons disease (PD) is unique to every person, with different early, middle, and late-stage symptoms. However, this view of PD progression may be an artifact of limited data rather than an accurate description Continue reading →

The idea of a cell therapy for Parkinsons disease starts out simple: Symptoms of the progressive disease are largely driven by the deaths of dopamine-producing neurons found deep within the brain. With lower levels of the neurotransmitter come the characteristic tremors, rigidity and slow movements. By replacing those lost nerve cells with new dopamine producers, researchers hope to renew the brains connection to the bodys muscles and improve a persons overall motor function. Continue reading →

Cerevance has initiated a Phase 2 clinical trial to evaluate the safety and efficacy of its oral investigational therapy CVN424 for treating Parkinsons disease motor symptoms. CVN424 is small molecule that can penetrate the brain and modulate the activity of specific nerve cells in the striatum region that control body movement Continue reading →

Seborrheic dermatitis is a skin condition that causes an itchy, flaky rash to develop on the scalp, face, or other parts of the body. Many people call it dandruff. Continue reading →

Shares in Intec Pharma have come under pressure again, following Novartis decision to exit a partnership focused on its Accordion drug delivery technology. Novartis has opted out of a January 2018 alliance to develop an Accordion formulation of an undisclosed drug in its pipeline, despite the project meeting the technical and pharmacokinetic specifications laid out in the contract terms, according to the Israeli company. Novartis has said the programme no longer fits with its mid- to long-term strategic goals, according to Intec, which saw its Nasdaq-listed shares fall by more than 12% after the announcement Continue reading →

FormerRev. Paul Burak was leaving a church Christmas party at a bar when he allegedly struck two women with his car. Continue reading →